Sean McCabe

2 months ago | jdsupra.com | Michael Discenza |Sean McCabe |Linnea Spagnoletti

On Jan. 31, 2025, a federal district court in Rhode Island entered a temporary restraining order (“TRO”) prohibiting all federal agencies from pausing, canceling or terminating any awards or obligations as directed by an Office of Management and Budget (“OMB”) Memorandum published by the Trump administration on Jan. 27, 2025. The TRO applies to all federal financial assistance programs and requires such agencies to comply with the TRO immediately.

Dec 3, 2024 | irishexaminer.com | Sean McCabe

It is Sunday morning, December 1, 2024, and as the election count unfolds, the airwaves hum with a familiar refrain. Pundits, politicians, and broadcasters extol the virtues of being "ready to govern" invoking metaphors of green jerseys and ditches while lauding the so-called "pragmatism" of being a “party of government”. These platitudes, presented as wisdom, are as much about shaping the future as they are about rewriting the past. This narrative isn't new.

Aug 12, 2024 | medicine.yale.edu | Sean McCabe

A Yale School of Medicine team reports in a new study, published in the journal Heliyon, that an artificial intelligence (AI) model was able to reliably diagnose people living with Marfan syndrome from a simple facial photograph. Marfan syndrome is a genetic disorder, affecting about 1 in 3,000 people, which impacts the body's connective tissues.

Mar 10, 2024 | thaihits.com | Sean McCabe

Switch to the dark mode that's kinder on your eyes at night time. Switch to the light mode that's kinder on your eyes at day time.

Jan 24, 2024 | medicine.yale.edu | Sean McCabe

One major hurdle in the development of safe and effective cancer immunotherapies has been the risk of depleting a patient’s healthy, disease-fighting T cells during treatments that seek to kill the cancerous T-cells in blood cancers, including leukemia and lymphoma. In a new study published in Nature Communications, Yale Cancer Center researchers have developed a novel CAR-T cell therapy designed to efficiently kill cancerous T cells while leaving most healthy cells intact.